English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Nucleoside reverse transcriptase inhibitors (NRTIs) have been the backbones of HIV therapy since introduced in the late 1980s. These HIV drugs act by blocking the viral reverse transcriptase activity that is crucial in the HIV life cycle. In a recent study published by Science, Fowler et al. (2014) have shown that such antiretroviral agents can inhibit P2X7 receptor (P2X7R)-mediated Alu RNA-induced activation of caspase-1 in retinal pigment epithelial (RPE) cells and ATP-induced activation of caspase-1 in macrophage cells, independently of reverse transcriptase inhibition.

frontiers in pharmacology

HIV drug nucleoside reverse transcriptase inhibitors as promising anti-inflammation therapeutics by targeting P2X7-dependent large pore formation: one stone for two birds?